Fig. 1 · Structure

Documents & Downloads

Abacavir

Cat. No. A11115 CAS 136470-78-5

Transcriptase inhibitor

Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM IC50 > 250 μM Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis [PMID: 24177359]
CCRF-CEM EC50 18 μM Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis [PMID: 24177359]
CCRF-CEM EC50 23 μM Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis [PMID: 24177359]
HeLa IC50 170 μM Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis [PMID: 24177359]
L1210 IC50 > 250 μM Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis [PMID: 24177359]
MT2 EC50 0.32 μM Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay [PMID: 19179082]
MT2 CC50 190 μM Cytotoxicity against human MT2 cells after 5 days [PMID: 19179082]

Abacavir Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Abacavir from 2 published references. In vitro models include B*57:01-KC; 721.220.B*57:01. In vivo models include B*57:01-Tg.

Abacavir In Vitro Studies

In B*57:01-KC, culture supernatant IFN-γ and IL-1β protein levels were below the detection limit (15.6 pg/mL) with or without Abacavir exposure at 100 μM for 12 h. In 721.220.B*57:01 cultures treated with Abacavir at 60 µM 20 h before the assay, Abacavir had no apparent impact on HLA-B*57:01 maturation in either the presence or absence of tapasin. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Abacavir and cytokine detection in culture supernatant

Cell-based study · B*57:01-KC [1]

B*57:01-KC were exposed to Abacavir at 100 μM for 12 h. Culture supernatant protein levels of IFN-γ and IL-1β remained below the detection limit (15.6 pg/mL) with or without Abacavir exposure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Protein levels of IFN-γ and IL-1β in the culture supernatantcytokine protein levels below the detection limit (15.6 pg/mL)[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Exposure duration
12 h
Method
abacavir exposure
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Abacavir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > HLA-B*57:01-expressing keratinocytes were immunologically activated by abacavir (S7)

Protein levels of IFN-γ and IL-1β in the culture supernatant: Protein levels of IFN-γ and IL-1β in the culture supernatant; comparator: without abacavir exposure — Results > HLA-B*57:01-expressing keratinocytes were immunologically activated by abacavir (S7)

Abacavir and HLA maturation

Cell-based study · 721.220.B*57:01 [2]

721.220.B*57:01 cells received Abacavir at 60 µM 20 h before the assay. Abacavir had no apparent impact on HLA-B*57:01 maturation in either the presence or absence of tapasin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maturation [acquisition of resistance to digestion with endoglycosidase-H (Endo-H)] of HLA-B*57:01 moleculesReported result Abacavir had no apparent impact on HLA-B*57:01 maturation in either the presence or absence of tapasin.[2]

Literature-Reported Treatment Conditions

Treatment concentration
60 µM
Exposure duration
20 h before the start of the assay
Method
added to 2 × 107 cells in 50 ml culture medium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Abacavir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > MHC I Pulse-Chase Maturation Assay (S68, S69, S70, S71, S73); Figure 4 legend (S243, S247)

Maturation [acquisition of resistance to digestion with endoglycosidase-H (Endo-H)] of HLA-B*57:01 molecules: Maturation [acquisition of resistance to digestion with endoglycosidase-H (Endo-H)] of HLA-B*57:01 molecules; comparator: in the absence of abacavir in otherwise identical conditions — Figure 4 legend (S243, S247)

Abacavir In Vivo Studies

B*57:01-Tg received Abacavir at 20 mg/body p.o. At 3 h after administration, epidermal expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1) increased. [1]

Abacavir and epidermal protein expression

Animal study · B*57:01-Tg [1]

B*57:01-Tg received Abacavir at 20 mg/body p.o. Expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1) increased in the epidermis 3 h after administration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1)Reported result increased expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1) in the epidermis of B*57:01-Tg[1]

Conditions shared by the study groups

Route
p.o.
Treatment course
3 h after abacavir administration
Vehicle
1% carboxymethyl cellulose aqueous solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Abacavir 20 mg/bodyvehicleincreased expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1) in the epidermis of B*57:01-Tg[1]
Abacavir 20 mg/body
Model: B*57:01-Tg
Methods and source locations

Compound reported in the paper: Abacavir

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > ER stress relief attenuated Abacavir-induced skin eruption in B*57:01-Tg (S35); Materials and methods > Animals (S76); Materials and methods > Histology and immunohistochemistry (S113, S115); Fig. 4. legend (S181, S182)

expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1): expression levels of phosphorylated IRE1α (p-IRE1α) and x-box binding protein 1 (XBP1); comparator: vehicle — Results > ER stress relief attenuated Abacavir-induced skin eruption in B*57:01-Tg (S35)

Abacavir 20 mg/body · Results > ER stress relief attenuated Abacavir-induced skin eruption in B*57:01-Tg (S35); Fig. 4. legend (S182)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 136470-78-5
Applications Transcriptase inhibitor
Formula C14H18N6O
Molecular Weight 286.3
SMILES
C1CC1NC2=NC(=NC3=C2N=CN3[C@@H]4C[C@@H](C=C4)CO)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (192.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Abacavir Research References

  1. [1] Kazaoka A, Fujimori S, Yamada Y, et al. HLA-B*57:01-dependent intracellular stress in keratinocytes triggers dermal hypersensitivity reactions to abacavir. PNAS Nexus (2024). PMID: 38628599 DOI: 10.1093/pnasnexus/pgae140 Source material
  2. [2] Illing PT, van Hateren A, Darley R, et al. Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. Front Immunol (2021). PMID: 34093574 DOI: 10.3389/fimmu.2021.672737 Source material

Added to your cart

View Cart Checkout
Loading...